



Silex

SYSTEMS LIMITED A.C.N. 003 372 067

Lucas Heights
Science & Technology Centre
New Illawarra Road
Lucas Heights NSW 2234 Australia
PO Box 75
Menai Central NSW 2234
Tel: (02) 9532 1331
Fax: (02) 9532 1332
www.silex.com.au

Appointment of Additional Non-Executive Director

2 July 2012

Silex Systems Limited ("Silex") (ASX: SLX) today announced the appointment of Dr Lisa McIntyre as an additional non-executive Director.

Silex Chairman Professor Steve Burdon said, "We are delighted that Lisa has joined the Silex Board. Lisa is an experienced company director and brings with her a unique set of high-technology, commercialisation and financial skills that will further strengthen and diversify the skill set of the Board."

Lisa is currently a non-executive Director of a number of well-known organisations and was formerly a senior partner in global strategic consultancy firm, L.E.K. Consulting, leading its Asia Pacific Life Science and Healthcare practice. During her career with L.E.K, Lisa also spent nine years in the firm's Boston office where she focused on growth and commercial issues facing the biotechnology sector. Lisa also currently serves on the 'ComEx Committee' for the CSIRO – Australia's premier Research and Development organisation. This Committee reviews all major commercial transactions that the CSIRO is involved with.

In accordance with Silex Systems' Articles of Association, Dr McIntyre will hold office until the 2012 Annual General Meeting on 7 November, at which time her election will be put to a shareholder vote.

Further Information

Further background information for Dr Lisa McIntyre is provided in the appendix to this announcement.

Further information on the Company's activities can be found on the Silex website: www.silex.com.au or by contacting the persons listed below.

Contacts: Michael Goldsworthy or Julie Ducie on + 61 2 9532 1331

Media: Alan Jury or David Akers (FTI Consulting) on +61 2 8298 6100



SilexSolar
Australian Clean Energy



Appendix

Biography – Dr Lisa McIntyre

Lisa McIntyre is a company director, corporate advisor, and former senior partner in global strategic consultancy L.E.K. Consulting. She led LEK's Asia Pacific Life Science and Healthcare practice which she developed to its market leading position.

In addition to strong sector, market and international business experience in Australia, North America and Asia, Lisa has deep financial and commercialisation skills. She works closely with the CEOs and boards of leading local and global companies on commercialisation strategies and business growth strategies, unlocking shareholder value, and geographic expansion.

Lisa holds a PhD in Physical Chemistry from Cambridge University, and a BSc (1st class, University Medal) in Biochemistry and Mathematics from the University of Sydney.

Directorships

Current

- Director of the Garvan Institute of Medical Research since 2002, and Chair of Business Development Advisory Committee since 2006
- ComEx Committee for CSIRO, a committee which reviews all major commercial transactions at CSIRO
- Director of the Hospitals Contribution Fund (HCF), the largest member-based private health insurance organisation in Australia
- Director of I-MED Network Pty Ltd, the largest provider of radiology services in Australia. Chair of Audit and Risk Committee
- Director of Tutoring Australasia, a private on-line education company founded by Lisa and her husband, since 2004 through a period of investment through to profitability

Previous

- Director of Atcor Medical Ltd from 2004-2008, an innovative medical device company which went public in 2005. Chaired the Audit Committee during a period of tight cash flow management.
- Biotech Capital Ltd (a public Venture Capital fund for biotechnology) from 2003 to 2008.
- Nominated Director for National Hearing Group (2010)
- Nominated Director for LifeHealthcare Pty Ltd (2011)

Forward Looking Statements and Business Risks:

Silex Systems is a research and development Company whose assets are its proprietary rights in various technologies, including, but not limited to, the SILEX technology, the SilexSolar technology and business, Solar Systems technology and business, Translucent technology and ChronoLogic technology. Several of the Company's technologies are in the development stage and have not been commercially deployed, and therefore are high-risk. Accordingly, the statements in this announcement regarding the future of the Company's technologies and commercial prospects are forward looking and actual results could be materially different from those expressed or implied by such forward looking statements as a result of various risk factors.

Some risk factors that could affect future results and commercial prospects include, but are not limited to: results from the SILEX uranium enrichment development program and the stable isotopes program; the demand for enriched materials including uranium, silicon, oxygen, carbon and others; the business risks associated with SilexSolar's activities; the risks associated with the development of Solar Systems technology and related marketing activities; the outcomes of the Company's interests in the development of various semiconductor, photonics and alternative energy technologies; the time taken to develop various technologies; the development of competing technologies; the potential for third party claims against the Company's ownership of Intellectual Property associated with its numerous technologies; the potential impact of government regulations or policies; and the outcomes of various commercialisation strategies undertaken by the Company.